Winning its second FDA approval this year, Boehringer Ingelheim's oral drug Jascayd is now cleared for use in the U.S. by ...

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...

Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient po | ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

CHICAGO, June 5, 2025 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF)'s, the nation's leading pulmonary fibrosis (PF) research, education, and advocacy organization, invites people living with ...

Here are the top 5 most-read pulmonary fibrosis articles of 2025.

Cystic fibrosis (CF) and pulmonary fibrosis (PF) are two chronic conditions that damage the lungs. Treatment for both aims to improve breathing, manage symptoms, and prevent further lung damage. Your ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...

The MarketWatch News Department was not involved in the creation of this content. CHICAGO, June 5, 2025 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF)'s, the nation's leading pulmonary ...